| Zacks Company Profile for Biogen Inc. (BIIB : NSDQ) |
|
|
| |
| • Company Description |
| Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
Number of Employees: 7,605 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $128.69 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 1,153,065 shares |
| Shares Outstanding: 146.53 (millions) |
| Market Capitalization: $18,856.67 (millions) |
| Beta: 0.14 |
| 52 Week High: $236.48 |
| 52 Week Low: $110.04 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
1.70% |
-3.41% |
| 12 Week |
7.68% |
-6.21% |
| Year To Date |
-15.85% |
-21.40% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
225 BINNEY STREET
-
CAMBRIDGE,MA 02142
USA |
ph: 617-679-2000
fax: 617-679-2617 |
ir@biogen.com |
http://www.biogen.com |
|
|
| |
| • General Corporate Information |
Officers
Christopher A. Viehbacher - Chief Executive Officer
Caroline D. Dorsa - Chair of the Board of Directors
Michael R. McDonnell - Executive Vice President and Chief Financial Offic
Robin C. Kramer - Senior Vice President; Chief Accounting Officer
Maria C. Freire - Director
|
|
Peer Information
Biogen Inc. (CORR.)
Biogen Inc. (RSPI)
Biogen Inc. (CGXP)
Biogen Inc. (BGEN)
Biogen Inc. (GTBP)
Biogen Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 09062X103
SIC: 2836
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 07/31/25
|
|
Share - Related Items
Shares Outstanding: 146.53
Most Recent Split Date: 1.00 (3.00:1)
Beta: 0.14
Market Capitalization: $18,856.67 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $3.96 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $14.84 |
Payout Ratio: 0.00 |
| Number of Estimates in the Fiscal Year Consensus: 26.00 |
Change In Payout Ratio: 0.00 |
| Estmated Long-Term EPS Growth Rate: 8.41% |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 07/31/25 |
|
|
|
| |
